Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech
In another declaration of its ongoing commitment to dealmaking, Celgene is turning to longtime partners at Triphase Accelerator for its latest preclinical asset.
The area …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.